<DOC>
	<DOCNO>NCT01997840</DOCNO>
	<brief_summary>Phase 1b : To evaluate side effect determine best dose ACY-1215 combination Pomalidomide low-dose dexamethasone patient relapsed-and-refractory multiple myeloma . Phase 2 : To determine overall response rate ACY-1215 combination Pomolidomide low-dose dexamethasone patient relapsed-and-refractory multiple myeloma</brief_summary>
	<brief_title>ACY-1215 ( Ricolinostat ) Combination With Pomalidomide Low-dose Dex Relapsed-and-Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Must document diagnosis multiple myeloma relapsedandrefractory disease . Patients must receive least 2 line prior therapy . Patients must relapse achieve least stable disease ( SD ) least one cycle treatment least one prior regimen develop progressive disease ( PD ) . Patients must also document evidence PD within 60 day ( measure end last cycle ) complete treatment last antimyeloma drug regimen use prior study entry ( refractory disease ) Must undergone prior treatment least 2 cycle lenalidomide least 2 cycle proteasome inhibitor ( either separate regimen within regimen ) Must candidate autologous stem cell transplant ( ASCT ) , decline option ASCT , relapse prior ASCT Must measurable level myeloma paraprotein serum ( ≥ 0.5 g/dL ) urine ( ≥ 0.2 g/24 hour ) Must Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 , 1 , 2 Females child bear potential ( FCBP ) must negative serum urine pregnancy test sensitivity least 25 mIU/mL within 10 14 day prior , within 24 hour start pomalidomide must either commit continued abstinence heterosexual intercourse begin TWO acceptable method birth control , one highly effective method one additional effective method AT THE SAME TIME , least 28 day start take pomalidomide . FCBP must also agree ongoing pregnancy test . Men must agree use latex condom sexual contact FCBP even vasectomy . All patient must counsel minimum every 28 day pregnancy precaution risk fetal exposure . Risks Fetal Exposure , Pregnancy Testing Guidelines Acceptable Birth Control Methods , Education Counseling Guidance must follow per protocol Must able take acetylsalicylic acid ( ASA ) ( 81 325 mg ) daily prophylactic anticoagulation . Patients intolerant ASA may use low molecular weight heparin . Lovenox recommend . Coumadin allow provide patient fully anticoagulated , international normalize ratio ( INR ) 2 3 Pregnant lactating female Prior therapy HDAC inhibitor Any follow laboratory abnormality : ANC &lt; 1,000/µL Platelet count &lt; 75,000/ µL patient &lt; 50 % bone marrow nucleate cell plasma cell ; &lt; 50,000/ µL patient ≥ 50 % bone marrow nucleate cell plasma cell Hemoglobin &lt; 8g/dL ( &lt; 4.9 mmol/L ; prior red blood cell [ RBC ] transfusion permit ) Creatine clearance &lt; 45mL/min accord CockcroftGault formula . If creatine clearance calculate 24hour urine sample ≥ 45 mL/min , patient qualify study Serum glutamic oxaloacetic transaminase ( SGOT ) /aspartate aminotransferase ( AST ) , serum glutamic pyruvic transaminase ( SGPT ) / alanine aminotransferase ( ALT ) &gt; 3.0 × ULN Serum total bilirubin &gt; 2.0 mg/dL Prior history malignancy , MM , unless patient free disease ≥ 3 year . Exceptions include follow : Basal squamous cell carcinoma skin Carcinoma situ cervix breast Incidental histologic find prostate cancer ( TNM stage T1a T1b ) Corrected QT interval use Fridericia 's formula ( QTcF ) value &gt; 480 msec screening ; family personal history long QTc syndrome ventricular arrhythmia include ventricular bigeminy ; previous history druginduced QTc prolongation need treatment medication know suspected produce prolonged QTc interval electrocardiogram ( ECG ) Positive human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) and/or hepatitis C virus ( HCV ) infection Hypersensitivity thalidomide , lenalidomide , dexamethasone ( Steven Johnson Syndrome ) . Hypersensitivity , rash , medically manage allowable Peripheral neuropathy ≥ Grade 2 despite supportive therapy Radiotherapy systemic therapy ( standard investigational biologic anticancer agent ) within 14 day initiation study drug treatment Current enrollment another clinical trial involve treatment and/or receive investigational agent reason Inability unwillingness comply birth control requirement regional REMS/RevAid program</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Neoplasms , Plasma Cell</keyword>
	<keyword>Neoplasms Histologic Type</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Blood Protein Disorders</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Dexamethasone acetate</keyword>
	<keyword>Pomalidomide</keyword>
</DOC>